Written by Keen Meds  ·  Reviewed by Licensed Clinical Providers  ·  March 1, 2026

Key Insight: Prevalence of hypogonadism increases substantially with age -- approximately 20% of men in their 50s meet clinical criteria for TRT. The TRAVERSE trial specifically enrolled men averaging age 66.

> Prevalence of hypogonadism increases substantially with age -- approximately 20% of men in their 50s meet clinical criteria for TRT. The TRAVERSE trial specifically enrolled men averaging age 66.

Medically reviewed by licensed clinical providers · March 2026

Men over 50 represent the primary TRT population -- not younger men seeking performance enhancement, and not a fringe cohort. Hypogonadism becomes progressively more prevalent with age, and the clinical evidence supporting TRT is largely built on data from men in their 50s, 60s, and older. The TRAVERSE trial, the most rigorous cardiovascular safety study of TRT ever conducted, enrolled men with an average age of 66. TRT works in this age group -- but the clinical picture, symptom presentation, monitoring requirements, and realistic expectations differ meaningfully from TRT at 35.

Why Men Over 50 Are the Primary TRT Population

Testosterone levels begin declining gradually after age 30, at a rate of approximately 1--2% per year. By age 50, many men have experienced a 20--30% reduction from their peak levels. By age 60, the cumulative decline is often substantial enough to produce clinically significant hypogonadism.

Approximately 20% of men in their 50s meet the clinical diagnostic criteria for hypogonadism: a total testosterone below 300 ng/dL on two separate fasting morning tests, combined with clinical symptoms. That percentage rises further in men over 60 and beyond.

This prevalence data explains why TRT is a middle-age and older-age medicine. The men who benefit most are those whose testosterone has fallen below the functional threshold -- which becomes increasingly common after 50.

How Symptoms Present Differently After 50

Low testosterone symptoms in younger men (under 40) often present with a relatively specific profile: reduced libido, erectile changes, and diminished energy. These are recognizable and tend to prompt investigation relatively quickly.

In men over 50, the symptom picture is more diffuse and more easily attributed to other causes. The most commonly reported symptoms in this age group include:

  • Fatigue and reduced stamina (often attributed to aging, sleep changes, or work stress)
  • Mood changes, including irritability, low motivation, and mild depression (often attributed to life circumstances)
  • Cognitive changes, including reduced sharpness, slower processing, and memory lapses (often attributed to normal aging)
  • Body composition changes -- loss of lean mass and gain of visceral fat -- independent of diet changes
  • Reduced bone density (often subclinical until a fracture occurs)
  • Reduced libido (present but sometimes less dominant as a complaint than in younger men)

The diffuse quality of these symptoms means low testosterone is frequently underdiagnosed in this age group. Men often adapt to gradual decline, reframing symptoms as inevitable aging rather than a potentially treatable hormonal state. A testosterone evaluation is appropriate for any man over 50 presenting with this symptom cluster.

The SHBG Factor: Why Total T Can Be Misleading

A critical clinical consideration for men over 50 is the age-related rise in sex hormone-binding globulin (SHBG). SHBG is a protein that binds testosterone in the bloodstream, making it unavailable for tissue uptake. As SHBG rises with age -- driven partly by increasing estrogen relative to testosterone -- the proportion of bioavailable "free" testosterone decreases.

The practical implication: a man in his 50s with a total testosterone of 350 ng/dL may have a free testosterone level that is functionally deficient, even though his total T appears marginally within the low-normal range. Evaluating free testosterone alongside total testosterone is standard clinical practice in older men and often clarifies cases where total T appears borderline but symptoms are pronounced.

Men who receive a testosterone evaluation should ensure their lab panel includes free testosterone -- particularly if total T comes back in the 300--400 ng/dL range.

Monitoring Differences at 50+

Men over 50 on TRT require the same monitoring as younger men -- but with a few areas of heightened attention:

PSA monitoring. Prostate-specific antigen should be checked before TRT initiation and at 3 months, then annually. The concern is not that TRT causes prostate cancer -- the evidence does not support this -- but that TRT can stimulate growth of pre-existing, subclinical prostate cancer. PSA monitoring is the clinical safeguard. Significant PSA rise (generally >1.4 ng/mL over 12 months or absolute value >4.0) warrants urological evaluation before continuing TRT.

Hematocrit monitoring. Polycythemia (elevated hematocrit from TRT) is more common in older men and in men with higher baseline hematocrit. The 2--5% prevalence figure for polycythemia in TRT literature rises meaningfully in men over 60. Regular CBC monitoring with hematocrit is essential, and dose adjustment may be needed more frequently in this age group.

Sleep apnea screening. Older men have higher baseline OSA prevalence, and testosterone can worsen existing sleep-disordered breathing. Screening for OSA symptoms before and during TRT is standard practice in men over 50.

Cardiovascular baseline. Given that cardiovascular risk increases with age, a baseline assessment of blood pressure, lipid panel, and cardiovascular risk factors is appropriate before starting TRT in men over 50.

Prostate Considerations: The Outdated Fear

For decades, the assumption that testosterone feeds prostate cancer kept many men with hypogonadism undertreated. This concern traces back to a 1941 observation that castration regressed prostate cancer -- a reasonable inference that led to the "testosterone fuels prostate cancer" narrative.

Subsequent research has not supported this inference for therapeutic TRT in men without active prostate cancer. The TRAVERSE prostate sub-study found no significant increase in serious prostate events -- including prostate cancer diagnosis, prostate biopsy, or acute urinary retention -- in testosterone-treated men compared to placebo over four years.

The current clinical standard: TRT is contraindicated in men with active prostate cancer. It is not contraindicated in men with a history of successfully treated, low-grade prostate cancer (a nuanced area requiring case-by-case evaluation), and it is not contraindicated in men with benign prostatic hyperplasia (BPH), though urinary symptom monitoring is appropriate.

Realistic Outcomes: 50 vs. 35

The benefit of TRT is real at 50, 60, and beyond. But the response profile differs from what a younger man might experience. Key realistic expectations for men over 50:

Energy and mood tend to show the most consistent improvement, often within the first 6--8 weeks. Men frequently describe a return of baseline motivation and reduced mental fog.

Libido improves in most men, though the degree of improvement may be more modest than in younger men -- partly because libido in older men is influenced by multiple factors beyond testosterone alone.

Body composition changes are real but gradual. Lean mass improvements and fat mass reductions at 50+ typically require 6--12 months and are more modest in absolute terms than in younger men. Resistance training remains essential for optimizing this effect.

Bone density is an under-recognized benefit of TRT in older men. The TRAVERSE bone sub-study found that testosterone-treated men had significantly less bone loss than placebo-treated men -- a meaningful finding given the fracture risk associated with age-related bone density decline.

Cognitive function shows mixed results in clinical literature, with some studies finding improvement in memory, spatial ability, and processing speed in hypogonadal men, and others finding no significant effect. This remains an active area of research.

When Not to Start TRT in Men Over 50

TRT is not appropriate for every man over 50 with low testosterone symptoms. Contraindications that are particularly relevant in this age group:

  • Active prostate cancer -- absolute contraindication
  • Recent acute cardiovascular event (heart attack, stroke, or major cardiac procedure within 3--6 months) -- defer until stable
  • Hematocrit above 54% before treatment -- address elevated hematocrit before initiating TRT
  • Severe untreated obstructive sleep apnea -- optimize OSA treatment before TRT
  • Desire to preserve fertility -- TRT suppresses sperm production, which may not be a concern for most men over 50 but should be discussed

These are clinical conversations for a licensed provider, not self-screening criteria. If you have questions about how these apply to your situation, a telehealth consultation is the appropriate forum.

Frequently Asked Questions

Is it too late to start TRT in my 60s or 70s?
Clinical evidence does not establish an upper age limit for TRT benefit. The TRAVERSE trial enrolled men with an average age of 66 and demonstrated improved bone density, body composition, and sexual function with no significant increase in cardiovascular events. Age itself is not a contraindication. The relevant question is whether you have confirmed hypogonadism, no active contraindications, and a monitoring plan in place.

Will TRT affect my PSA or prostate?
TRT can cause a modest PSA increase in some men during the first 3--6 months of therapy as prostate tissue responds to restored androgen signaling. This is generally not clinically significant but is monitored. Sustained PSA elevation or accelerated PSA rise warrants urological evaluation. TRT does not appear to cause prostate cancer based on current evidence, including the TRAVERSE prostate sub-study.

How does TRT delivery method matter for men over 50?
Daily transdermal delivery -- as with Keen's Testosterone Spray Rx via Hypospray® -- provides stable daily levels without the pronounced peaks of less frequent injection schedules. For older men, who may have higher hematocrit sensitivity, stable daily levels help minimize polycythemia risk while maintaining consistent therapeutic benefit. Daily application also allows for immediate dose adjustment if needed -- an important consideration given the increased monitoring complexity in this age group.

Start with a Clinical Evaluation

If you are over 50 and experiencing symptoms associated with low testosterone -- fatigue, mood changes, body composition shifts, reduced libido, or poor sleep -- a testosterone evaluation is a clinically appropriate starting point.

Keen Meds connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, you receive a prescription for Testosterone Spray Rx -- delivered via Hypospray®, Keen's needle-free transdermal spray platform.

Start your Keen Testosterone Spray Program →

Medically reviewed by Licensed Clinical Providers · March 2026

Related reading: